Influence of the tumor site and histopathology after resection for non-colorectal non-neuroendocrine liver metastases. A single center experience

被引:0
|
作者
De-Armas-Conde, Noelia [1 ]
Ramon-Rodriguez, Julen [1 ]
Prada-Villaverde, Aranzazu [1 ]
Jaen-Torrejimeno, Isabel [1 ]
Lopez-Guerra, Diego [1 ,2 ]
Blanco-Fernandez, Gerardo [1 ,2 ]
机构
[1] Complejo Hosp Univ Badajoz, Serv Cirugia Gen & Digest, Unidad Cirugia HPB & Trasplante Hepat, Badajoz, Spain
[2] Univ Extremadura, Fac Med, Badajoz, Spain
来源
CIRUGIA ESPANOLA | 2023年 / 101卷 / 06期
关键词
Liver neoplasm; Metastases; Non colorectal non neuroendocrine; Hepatectomy; Liver resection; HEPATIC RESECTION; CLASSIFICATION; SURVIVAL;
D O I
10.1016/j.ciresp.2022.04.003
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: It remains unclear whether liver resection is justified in patients with non colorectal non-neuroendocrine liver metastases (NCNNLM). A single-center study was conducted to analyse overall survival (OS), disease-free survival (DFS), and potential prognostic factors in patients with different types of NCNNLM. Method: A retrospective analysis of all patients who underwent liver resection of NCNNLM from January 2006 to July 2019 was performed. Results: A total of 62 patients were analyzed. 82.3% presented metachronous metastases and 74.2% were unilobar. The most frequent primary tumor site (PTS) were breast (24.2%), urinary tract (19.4%), melanoma (12.9%), and pancreas (9.7%). The most frequent primary tumor pathologies were breast carcinoma (24.2%), non-breast adenocarcinoma (21%), melanoma (12.9%) and sarcoma (12.9%). The most frequent surgical procedure performed was minor hepatectomy (72.6%). R0 resection was achieved in 79.5% of cases. The major complications' rate was 9.7% with a 90-day mortality rate of 1.6%. The 1, 3 and 5-year OS/DFS rate were 65%/28%, 45%/36% and 46%/28%, respectively. We identified the response to neoadjuvant therapy and PTS as possible prognostic factors for OS (P =0.06) and DFS (P =0.06) respectively. Conclusion: Based on the results of our series, NCNNLM resection produces beneficial outcomes in terms of OS and DFS. PTS and the response to neoadjuvant therapy could be the main prognostic factors after resection. (c) 2022 Published by Elsevier Espana, S.L.U. on behalf of AEC.
引用
收藏
页码:397 / 407
页数:11
相关论文
共 50 条
  • [31] Neoadjuvant chemotherapy response influences outcomes in non-colorectal, non-neuroendocrine liver metastases
    Lucchese, A. M.
    Kalil, A. N.
    Ruiz, A.
    Karam, V
    Ciacio, O.
    Pittau, G.
    Castaing, D.
    Cherqui, D.
    Cunha, A. Sa
    Vibert, E.
    Adam, R.
    BRITISH JOURNAL OF SURGERY, 2018, 105 (12) : 1665 - 1670
  • [32] Liver resection for non-colorectal metastases
    Christoph Schwarz
    Klaus Kaczirek
    Martin Bodingbauer
    European Surgery, 2018, 50 : 113 - 116
  • [33] Non-colorectal non-neuroendocrine liver metastasis: a narrative review of surgical treatment
    Del Basso, Celeste
    Usai, Sofia
    Sandri, Giovanni Battista Levi
    CHINESE CLINICAL ONCOLOGY, 2022, 11 (04)
  • [34] Liver resection for non-colorectal metastases
    Schwarz, Christoph
    Kaczirek, Klaus
    Bodingbauer, Martin
    EUROPEAN SURGERY-ACTA CHIRURGICA AUSTRIACA, 2018, 50 (03): : 113 - 116
  • [35] Liver resection for metastases of non-colorectal primary tumors
    Seifert, JK
    Junginger, T
    CHIRURG, 1996, 67 (02): : 161 - 168
  • [36] Histopathological growth patterns of resected non-colorectal, non-neuroendocrine liver metastases: a retrospective multicenter studyss
    Meyer, Yannick
    Bohlok, Ali
    Hoppener, Diederik
    Galjart, Boris
    Doukas, Michail
    Grunhagen, Dirk J.
    Labar, Anais
    Lucidi, Valerio
    Vermeulen, Peter B.
    Verhoef, Cornelis
    Donckier, Vincent
    CLINICAL & EXPERIMENTAL METASTASIS, 2022, 39 (03) : 433 - 442
  • [37] Histopathological growth patterns of resected non-colorectal, non-neuroendocrine liver metastases: a retrospective multicenter study
    Yannick Meyer
    Ali Bohlok
    Diederik Höppener
    Boris Galjart
    Michail Doukas
    Dirk J. Grünhagen
    Anaïs Labar
    Valerio Lucidi
    Peter B. Vermeulen
    Cornelis Verhoef
    Vincent Donckier
    Clinical & Experimental Metastasis, 2022, 39 : 433 - 442
  • [38] Metastatic liver disease from non-colorectal, non-neuroendocrine, non-sarcoma cancers: a systematic review
    Uggeri, Fabio
    Ronchi, Paolo Alessandro
    Goffredo, Paolo
    Garancini, Mattia
    Degrate, Luca
    Nespoli, Luca
    Gianotti, Luca
    Romano, Fabrizio
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2015, 13
  • [39] Hepatectomy for liver metastases in non-colorectal, non-neuroendocrine cancer patients. The survival benefit in primary unresectable cases
    Maeda, Yoshiaki
    Shinohara, Toshiki
    Katayama, Tomonari
    Futakawa, Noriaki
    Hamada, Tomonori
    INTERNATIONAL JOURNAL OF SURGERY, 2015, 22 : 136 - 142
  • [40] Comparison of surgical outcomes in patients with colorectal liver metastases versus non-colorectal liver metastases: A Chinese experience
    Duan, Xiao-Feng
    Dong, Na-Na
    Zhang, Ti
    Li, Qiang
    HEPATOLOGY RESEARCH, 2012, 42 (03) : 296 - 303